Reviewing Northwest Biotherapeutics (OTCMKTS:NWBO) and Pharmaxis (OTCMKTS:PXSLY)

Northwest Biotherapeutics (OTCMKTS:NWBOGet Free Report) and Pharmaxis (OTCMKTS:PXSLYGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.


This table compares Northwest Biotherapeutics and Pharmaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Northwest Biotherapeutics -5,258.91% N/A -241.52%
Pharmaxis N/A N/A N/A

Earnings & Valuation

This table compares Northwest Biotherapeutics and Pharmaxis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Northwest Biotherapeutics $1.93 million 291.83 -$62.60 million ($0.07) -6.57
Pharmaxis $8.75 million 3.03 -$9.36 million N/A N/A

Pharmaxis has higher revenue and earnings than Northwest Biotherapeutics.

Insider & Institutional Ownership

0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 8.7% of Northwest Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Northwest Biotherapeutics and Pharmaxis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Northwest Biotherapeutics 0 0 0 0 N/A
Pharmaxis 0 0 0 0 N/A

Volatility & Risk

Northwest Biotherapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, Pharmaxis has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.


Pharmaxis beats Northwest Biotherapeutics on 5 of the 8 factors compared between the two stocks.

About Northwest Biotherapeutics

(Get Free Report)

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Pharmaxis

(Get Free Report)

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with's FREE daily email newsletter.